Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIZTOX in Benign Masseteric Hypertrophy
NCT05964257Phase 3Active, not recruiting
- Sponsor
- Huons Biopharma
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of hutox in benign masseteric hypertrophy (BMH), sponsored by Huons Biopharma. Started Jul 2023; status: active, not recruiting.
02
Drugs
hutox
03
Conditions
benign masseteric hypertrophy (BMH)
Beyond the preview
Go deeper on NCT05964257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964257.